{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T01:13:27Z","timestamp":1772068407381,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM130423"],"award-info":[{"award-number":["P20GM130423"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR002367"],"award-info":[{"award-number":["KL2TR002367"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5U24-TR001608-04"],"award-info":[{"award-number":["5U24-TR001608-04"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["3U24-TR001608-04S1"],"award-info":[{"award-number":["3U24-TR001608-04S1"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01 HD089928"],"award-info":[{"award-number":["R01 HD089928"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HHSN275201800003I"],"award-info":[{"award-number":["HHSN275201800003I"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Inadequate systemic exposure to infliximab (IFX) is associated with treatment failure. This work evaluated factors associated with reduced IFX exposure in children with autoimmune disorders requiring IFX therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this single-center cross-sectional prospective study IFX trough concentrations and anti-drug antibodies (ADAs) were measured in serum from children diagnosed with inflammatory bowel disease (IBD) (<jats:italic>n<\/jats:italic>\u2009=\u200973), juvenile idiopathic arthritis (JIA) (<jats:italic>n<\/jats:italic>\u2009=\u200916), or uveitis (<jats:italic>n<\/jats:italic>\u2009=\u20098) receiving maintenance IFX infusions at an outpatient infusion clinic in a tertiary academic pediatric hospital. IFX concentrations in combination with population pharmacokinetic modeling were used to estimate IFX clearance. Patient demographic and clinical data were collected by chart review and evaluated for their relationship with IFX clearance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>IFX trough concentrations ranged from 0 to &gt;\u200940\u2009\u03bcg\/mL and were 3-fold lower in children with IBD compared to children with JIA (<jats:italic>p<\/jats:italic>\u2009=\u20090.0002) or uveitis (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). Children with IBD were found to receive lower IFX doses with longer dosing intervals, resulting in dose intensities (mg\/kg\/day) that were 2-fold lower compared to children with JIA (<jats:italic>p<\/jats:italic>\u2009=\u20090.0002) or uveitis (<jats:italic>p<\/jats:italic>\u2009=\u20090.02). Use of population pharmacokinetic analysis to normalize for variation in dosing practices demonstrated that increased IFX clearance was associated with ADA positivity (<jats:italic>p<\/jats:italic>\u2009=\u20090.004), male gender (<jats:italic>p<\/jats:italic>\u2009=\u20090.02), elevated erythrocyte sedimentation rate (ESR) (p\u2009=\u20090.02), elevated c-reactive protein (CRP) (<jats:italic>p<\/jats:italic>\u2009=\u20090.001), reduced serum albumin concentrations (<jats:italic>p<\/jats:italic>\u2009=\u20090.0005), and increased disease activity in JIA (<jats:italic>p<\/jats:italic>\u2009=\u20090.009) and IBD (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.08). No significant relationship between diagnosis and underlying differences in IFX clearance was observed. Multivariable analysis by covariate population pharmacokinetic modeling confirmed increased IFX clearance to be associated with anti-IFX antibody positivity, increased ESR, and reduced serum albumin concentrations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Enhanced IFX clearance is associated with immunogenicity and inflammatory burden across autoimmune disorders. Higher systemic IFX exposures observed in children with rheumatologic disorders are driven primarily by provider drug dose and interval selection, rather than differences in IFX pharmacokinetics across diagnoses. Despite maintenance IFX dosing at or above the standard recommended range for IBD (i.e., 5\u2009mg\/kg every 8\u2009weeks), the dosing intensity used in the treatment of IBD is notably lower than dosing intensities used to treat JIA and uveitis, and may place some children with IBD at risk for suboptimal maintenance IFX exposures necessary for treatment response.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-021-00548-8","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T11:43:03Z","timestamp":1620042183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3834-4672","authenticated-orcid":false,"given":"Ryan S.","family":"Funk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Shakhnovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Kyoung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kishore","family":"Polireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taina","family":"Jausurawong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Gress","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara L.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"548_CR1","first-page":"139","volume":"13","author":"R Melsheimer","year":"2019","unstructured":"Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade((R)) (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139\u201378.","journal-title":"Biologics."},{"issue":"16","key":"548_CR2","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","volume":"30","author":"DM Knight","year":"1993","unstructured":"Knight DM, Trinh H, Le JM, et al. Construction and initial characterization of a mouse-human chimeric anti-Tnf antibody. Mol Immunol. 1993;30(16):1443\u201353.","journal-title":"Mol Immunol"},{"issue":"3","key":"548_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132(3):863\u201373 quiz 1165-1166.","journal-title":"Gastroenterology."},{"issue":"9","key":"548_CR4","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/ard.2010.143347","volume":"70","author":"P Tynjala","year":"2011","unstructured":"Tynjala P, Vahasalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early Polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70(9):1605\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"548_CR5","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3899\/jrheum.130133","volume":"40","author":"A Tambralli","year":"2013","unstructured":"Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40(10):1749\u201355.","journal-title":"J Rheumatol"},{"key":"548_CR6","doi-asserted-by":"crossref","unstructured":"Henderson LA, Zurakowski D, Angeles-Han ST, et al. Medication use in juvenile uveitis patients enrolled in the childhood arthritis and rheumatology research Alliance registry. Pediatr Rheumatol. 2016;14(1):9.","DOI":"10.1186\/s12969-016-0069-5"},{"key":"548_CR7","doi-asserted-by":"publisher","first-page":"765380","DOI":"10.5402\/2012\/765380","volume":"2012","author":"S Sukumaran","year":"2012","unstructured":"Sukumaran S, Marzan K, Shaham B, Reiff A. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol. 2012;2012:765380.","journal-title":"ISRN Rheumatol"},{"issue":"5","key":"548_CR8","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","volume":"113","author":"P Kahn","year":"2006","unstructured":"Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860\u20134 e862.","journal-title":"Ophthalmology."},{"key":"548_CR9","doi-asserted-by":"publisher","first-page":"204062231983844","DOI":"10.1177\/2040622319838443","volume":"10","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis. 2019;10:2040622319838443.","journal-title":"Ther Adv Chronic Dis"},{"issue":"7","key":"548_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/kem075","volume":"46","author":"MH Buch","year":"2007","unstructured":"Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford). 2007;46(7):1153\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"548_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","volume":"63","author":"F Cornillie","year":"2014","unstructured":"Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63(11):1721\u20137.","journal-title":"Gut."},{"issue":"9","key":"548_CR12","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096\u2013106.","journal-title":"Arthritis Rheum"},{"key":"548_CR13","unstructured":"University of Maryland Center for Excellence in Regulatory Science and Innovation and the Food and Drug Administration. Accelerating Drug Development for Polyarticular Juvenile Idiopathic Arthritis (pJIA). https:\/\/cersi.umd.edu\/accelerating-drug-development-polyarticular-juvenile-idiopathic-arthritis-pjia. Published 2019. Accessed 6 Dec 2019."},{"issue":"7","key":"548_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601\u20138.","journal-title":"N Engl J Med"},{"issue":"8","key":"548_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","volume":"57","author":"A Hemperly","year":"2018","unstructured":"Hemperly A, Vande CN. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018;57(8):929\u201342.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"548_CR16","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","volume":"20","author":"I Dotan","year":"2014","unstructured":"Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247\u201359.","journal-title":"Inflamm Bowel Dis"},{"key":"548_CR17","doi-asserted-by":"crossref","unstructured":"Bauman LE, Xiong Y, Mizuno T, et al. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;26(3):429-39.","DOI":"10.1093\/ibd\/izz143"},{"key":"548_CR18","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1038\/clpt.2010.263","volume":"89","author":"JL Goldman","year":"2011","unstructured":"Goldman JL, Davis HM, Zhou H, Kearns GL. Association of Infliximab Clearance and Resting Energy Expenditure in children. Clin Pharmacol Ther. 2011;89:S3.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"548_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/bcp.12313","volume":"78","author":"D Ternant","year":"2014","unstructured":"Ternant D, Ducourau E, Perdriger A, et al. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol. 2014;78(1):118\u201328.","journal-title":"Br J Clin Pharmacol"},{"key":"548_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cca.2015.12.015","volume":"453","author":"IY Pavlov","year":"2016","unstructured":"Pavlov IY, Carper J, Lazar-Molnar E, Delgado JC. Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximab. Clin Chim Acta. 2016;453:147\u201353.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"548_CR21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","volume":"33","author":"AA Fasanmade","year":"2011","unstructured":"Fasanmade AA, Adedokun OJ, Blank M, Zhou HH, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946\u201364.","journal-title":"Clin Ther"},{"key":"548_CR22","unstructured":"Monolix version 2019R2. http:\/\/monolix.lixoft.com. Published 2019. Accessed 29 Apr 2020."},{"issue":"5","key":"548_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF01061469","volume":"20","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20(5):511\u201328.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"548_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/ecco-jcc\/jjy155","volume":"13","author":"B Kang","year":"2019","unstructured":"Kang B, Choi SY, Choi YO, et al. Infliximab trough levels are associated with mucosal healing during maintenance treatment with infliximab in Paediatric Crohn's disease. J Crohns Colitis. 2019;13(2):189\u201397.","journal-title":"J Crohns Colitis"},{"key":"548_CR25","doi-asserted-by":"crossref","unstructured":"Jongsma MME, Winter DA, Huynh HQ, et al. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr. 2020;179(12):1935-44.","DOI":"10.1007\/s00431-020-03750-0"},{"issue":"6","key":"548_CR26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/MPG.0000000000002631","volume":"70","author":"DA Winter","year":"2020","unstructured":"Winter DA, Joosse ME, de Wildt SN, Taminiau J, de Ridder L, Escher JC. Pharmacokinetics, pharmacodynamics, and immunogenicity of infliximab in pediatric inflammatory bowel disease: a systematic review and revised dosing considerations. J Pediatr Gastroenterol Nutr. 2020;70(6):763\u201376.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"548_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/0394632015593220","volume":"29","author":"F Carubbi","year":"2016","unstructured":"Carubbi F, Zugaro L, Cipriani P, et al. Safety and efficacy of intra-articular anti-tumor necrosis factor alpha agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. Int J Immunopathol Pharmacol. 2016;29(2):252\u201366.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"548_CR28","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/rheumatology\/kes318","volume":"52","author":"ML Stoll","year":"2013","unstructured":"Stoll ML, Morlandt AB, Teerawattanapong S, Young D, Waite PD, Cron RQ. Safety and efficacy of intra-articular infliximab therapy for treatment-resistant temporomandibular joint arthritis in children: a retrospective study. Rheumatology (Oxford). 2013;52(3):554\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"548_CR29","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","volume":"23","author":"JF Brandse","year":"2017","unstructured":"Brandse JF, Mould D, Smeekes O, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):650\u201360.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"548_CR30","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1208\/s12248-017-0148-7","volume":"19","author":"ZD Zhong","year":"2017","unstructured":"Zhong ZD, Clements-Egan A, Gorovits B, et al. Drug target interference in immunogenicity assays: recommendations and mitigation strategies. AAPS J. 2017;19(6):1564\u201375.","journal-title":"AAPS J"},{"key":"548_CR31","doi-asserted-by":"publisher","first-page":"3072586","DOI":"10.1155\/2016\/3072586","volume":"2016","author":"S Song","year":"2016","unstructured":"Song S, Yang L, Trepicchio WL, Wyant T. Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance. J Immunol Res. 2016;2016:3072586.","journal-title":"J Immunol Res"},{"issue":"9","key":"548_CR32","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552\u201363.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"548_CR33","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/ibd\/izy010","volume":"24","author":"LY Chi","year":"2018","unstructured":"Chi LY, Zitomersky NL, Liu E, et al. The impact of combination therapy on infliximab levels and antibodies in children and Young adults with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(6):1344\u201351.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"548_CR34","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","volume":"63","author":"C Steenholdt","year":"2014","unstructured":"Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919\u201327.","journal-title":"Gut."},{"issue":"11-12","key":"548_CR35","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.14368","volume":"46","author":"N Mitrev","year":"2017","unstructured":"Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11-12):1037\u201353.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"548_CR36","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/ibd\/izy399","volume":"25","author":"A Vasudevan","year":"2019","unstructured":"Vasudevan A, Gibson PR, Van Langenberg DR. Systematic review: cost-effective strategies of optimizing anti-tumor necrosis and Immunomodulators in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(9):1462\u201373.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"548_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13063-019-3734-4","volume":"21","author":"SW Syversen","year":"2020","unstructured":"Syversen SW, Goll GL, Jorgensen KK, et al. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials. 2020;21(1):13.","journal-title":"Trials."}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00548-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00548-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00548-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T21:07:05Z","timestamp":1626815225000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00548-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00548-8","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"16 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved under the Children\u2019s Mercy Kansas City institutional review board. Written informed consent\/assent was acquired prior to inclusion of subjects in the study and collection of patient data and samples.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}